Collegium Pharmaceutical (COLL) Sees Unusually-High Trading Volume on Analyst Upgrade

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares saw unusually-strong trading volume on Tuesday after Needham & Company LLC raised their price target on the stock from $25.00 to $28.00. Needham & Company LLC currently has a buy rating on the stock. Approximately 2,355,241 shares changed hands during mid-day trading, an increase of 365% from the previous session’s volume of 506,366 shares.The stock last traded at $17.74 and had previously closed at $16.94.

COLL has been the topic of a number of other reports. Piper Jaffray Companies reissued a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, November 13th. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, November 8th. Finally, Jefferies Group restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $22.67.

In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $17.00, for a total transaction of $68,493.00. Following the transaction, the chief technology officer now owns 28,513 shares in the company, valued at $484,721. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the transaction, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Insiders sold 58,630 shares of company stock worth $924,360 in the last 90 days. Company insiders own 25.76% of the company’s stock.

A number of hedge funds have recently modified their holdings of COLL. Sectoral Asset Management Inc boosted its position in Collegium Pharmaceutical by 41.4% during the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after purchasing an additional 529,503 shares in the last quarter. Citadel Advisors LLC boosted its position in Collegium Pharmaceutical by 773.8% during the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after purchasing an additional 481,771 shares in the last quarter. Macquarie Group Ltd. boosted its position in Collegium Pharmaceutical by 37.1% during the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock worth $13,995,000 after purchasing an additional 302,892 shares in the last quarter. Prudential Financial Inc. boosted its position in Collegium Pharmaceutical by 62.8% during the third quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock worth $5,843,000 after purchasing an additional 214,860 shares in the last quarter. Finally, Pura Vida Investments LLC purchased a new position in Collegium Pharmaceutical during the third quarter worth approximately $1,229,000. Institutional investors own 79.98% of the company’s stock.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. Collegium Pharmaceutical’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.13) earnings per share. analysts predict that Collegium Pharmaceutical, Inc. will post -2.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical (COLL) Sees Unusually-High Trading Volume on Analyst Upgrade” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/07/collegium-pharmaceutical-coll-sees-unusually-high-trading-volume-on-analyst-upgrade.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit